Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3139 in advanced cancer
NCT03099330Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of envonalkib in solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 48 weeks, Dose-Limiting Toxicity at 4 weeks and 5 more. Status: unknown.
02
Drugs
envonalkib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03099330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099330.